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Realistic and discriminative in vitro release in pH 6.8 [B] physiological bicarbonate buffer compared 
to [A] compendial phosphate buffer for enteric coated formulations
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Abstract 
The use of pH 6.8 compendial phosphate buffer to assess the release of enteric coated products 
gives rise to poor in vitro in vivo correlations because of the inadequacy of the buffer to resemble 
small intestinal fluids. A more representative and physiological medium, pH 6.8 bicarbonate buffer, 
was developed here to evaluate the dissolution behaviour of enteric coatings. The bicarbonate 
system was evolved from pH 7.4 Hanks balanced salt solution to produce a pH 6.8 bicarbonate 
buffer (modified Hanks buffer, mHanks), which resembles the ionic composition and buffer capacity 
of intestinal fluid. Tablets containing prednisolone were coated with a range of enteric polymers: 
hypromellose phthalate (HP-50 and HP-55), cellulose acetate phthalate (CAP), hypromellose acetate 
succinate (HPMCAS-LF and HPMCAS-MF), methacrylic acid copolymers (EUDRAGIT® L100-55, 
EUDRAGIT® L30D-55 and EUDRAGIT® L100) and polyvinyl acetate phthalate (PVAP). Dissolution of 
coated tablets was carried out using USP-II apparatus in 0.1 M HCl for 2 h, and subsequently pH 6.8 
phosphate buffer or pH 6.8 mHanks bicarbonate buffer. In pH 6.8 phosphate buffer, the various 
enteric polymer coats displayed rapid and comparable dissolution profiles. In pH 6.8 mHanks buffer, 
drug release was slow and marked differences were observed between the various coatings, which is 
comparable to the reported delayed disintegration times for enteric coated products in the small 
intestine. In summary, the use of pH 6.8 physiological bicarbonate buffer (mHanks) provides more 
realistic and discriminative in vitro release assessment for enteric coated formulations compared to 
compendial phosphate buffer. 
 
Key words: pH-sensitive polymers; enteric polymers; enteric coatings; modified release; 
physiological buffers; bicarbonate media; biorelevant dissolution 
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1. Introduction 
 
The application of an enteric coating to a solid dosage form is a well established approach to 
prevent drug release in the stomach and allow release in the small intestine.  It is used to 
preclude the degradation of acid-labile actives in the gastric environment or to protect the 
stomach from irritant compounds [1]. The commonly used enteric coatings employ pH-
dependent polymers which contain carboxylic groups.  These remain un-ionized in the low 
pH environment of the stomach, and become ionized in the higher pH conditions of the 
small intestine, thus allowing the dissolution of the coating and drug release.   
 
The in vitro dissolution performance of enteric coatings is usually assessed in compendial pH 
6.8 phosphate buffer. In this medium, drug release is typically rapid [3, 6, 9, 19]. However, 
neither does this reflect the in vivo performance of enteric coated products, nor it is 
sufficient to discriminate the dissolution behaviour between different enteric coatings. In 
vivo gamma scintigraphy studies have shown that there is a substantial time delay (up to 2 
h) for such products to disintegrate in the human small intestine post gastric emptying, with 
different enteric polymer coatings exhibiting varying disintegration times [4, 8, 12, 20, 39]. 
This in vitro-in vivo discrepancy is not surprising considering the inadequacy of the in vitro 
dissolution medium to resemble the luminal fluid of the small intestine in many respects 
such as ionic composition, buffer capacity, viscosity and volume [2, 11, 18, 25, 26, 33]. 
 
The constituent buffer salts, ionic strength and buffer capacity of the dissolution media have 
been reported to influence drug release from pH-responsive polymer coated dosage forms 
[7, 15, 22, 26]. Notebly, the luminal fluids of the small intestine are buffered by bicarbonate 
and phosphate levels are very low. Hence, bicarbonate buffers more closely resemble the 
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environment within the small intestine and would provide a more physiological media for 
the in vitro assessment of enteric products.  
 
We have shown that a pH 7.4 bicarbonate system (Krebs buffer), which simulates the 
luminal environment of the distal small intestine, provided better in vitro-in vivo correlations 
for a series of enteric coated products for delivery of mesalazine to the ileo-colonic region of 
the gastrointestinal tract [17]. Conventional bicarbonate buffers are “stable” at a pH of 7.4, 
however this pH is typically higher than the pH in the proximal small intestine [14]. The 
objective of this study was to develop a pH 6.8 bicarbonate system, based on Hanks buffer. 
This physiological medium was then employed to evaluate the dissolution behaviour of a 
series of enteric polymers from different chemical classes. 
 
2. Materials and Methods  
 
2.1 Materials 
The enteric polymers used in this study and their properties are listed in Table 1. 
Prednisolone was purchased from Aventis Pharma., Antony, France. Lactose (Pharmatose) 
was obtained from Ellis & Everard, Essex, UK.  Cross-linked sodium carboxymethylcellulose 
was donated by FMC International, Cork, Ireland. Polyvinylpyrrolidone 40,000 was 
purchased from VWR International Ltd, Poole, UK. Magnesium stearate was purchased from 
Sigma-Aldrich Co. Ltd., Dorset, UK. Triethyl citrate was obtained from Lancaster Synthesis, 
Lancashire, UK. Sodium lauryl sulphate and triacetin were sourced from Sigma-Aldrich Co. 
Ltd., Dorset, UK. Talc (fine powder) was purchased from VWR International Ltd, Poole, UK. 
Organic solvents used were of analytical grade and were obtained from VWR International 
Ltd, Poole, UK (ethanol) and Fisher Scientific UK Ltd, Loughborough, UK (acetone and 
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isopropanol). Salts for preparing buffer solutions were obtained from VWR International Ltd, 
Poole, UK. 
 
2.2 Preparation of prednisolone tablets 
Tablets were prepared containing 5% prednisolone, 88.5% lactose, 5% polyvinylpyrrolidone, 
0.5% cross-linked sodium carboxymethylcellulose and 1% magnesium stearate. Tablets were 
prepared by wet granulation and were produced using a single punch tableting machine 
(Manesty F3, Liverpool, UK). Cross-linked sodium carboxymethylcellulose (disintegrant) was 
added both intra- and extra-granularly (50:50). A biconcave 8 mm punch and die set 
(I Holland, Nottingham, UK) was used to obtain tablets of mass 200 mg (containing 10 mg 
drug) and crushing strength of 80 N.  
 
2.3 Coating of prednisolone tablets 
Enteric coating formulations were prepared either from aqueous polymer dispersions or 
organic solutions. The compositions of the aqueous and organic coating formulations are 
listed in Table 2.  
 
Prednisolone tablets were coated using a Strea-1 bottom spray fluidised bed coater 
(Aeromatic AG, Bubendorf, Switzerland). The coating conditions were optimised for each 
polymer formulation and are summarized in Table 3. Coating levels of the polymers were 
determined by the applied amount of polymer per centimetre square of tablet surface 
(mg/cm2), except for PVAP where percentage tablet weight gain (TWG %) was used (Table 
3). This is because the quantitative composition of the PVAP formulation is not known. After 
the coating process the tablets were cured in an air-assisted oven at 40°C for 2 hours.  
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2.4 Dissolution of enteric coated tablets 
 
2.4.1 Acid uptake 
All enteric coating formulations at each coating level were evaluated for acid-resistance and 
uptake. Six coated tablets of each formulation were weighed and subjected to dissolution 
conditions in 0.1 M HCl. After 2 hours the tablets were removed and excess medium was 
drained and blotted with filter paper from around the tablets. The tablets were weighed 
again and the acid uptake by the tablet was calculated according to Equation 1. 
Formulations were chosen for dissolution testing at the minimum coating level that met the 
criteria for acid protection, i.e., no more than 10% acid uptake and no visible signs of coat 
disruption after two hours acid treatment. 
 
Equation 1. 
Where Wf is the final tablet weight, Wi is the initial tablet weight. 
 
 
2.4.2 Development of physiological bicarbonate buffer (mHanks) 
Hanks balanced salt solution closely resembles the ionic composition of the small intestinal 
fluids; however, it has a pH of 7.4, which is too high, and a buffer capacity of 1 mmol/L/∆pH, 
which is too low, compared to human jejunal fluids. Therefore this buffer was modified to 
achieve a pH of 6.8 and a higher and more relevant buffer capacity (Table 4). Hanks solution 
is primarily a bicarbonate buffer, in which bicarbonate (HCO3
-) and carbonic acid (H2CO3) 
co-exist, along with CO2 (aq) resultant from the dissociation of the latter (Equation 2).   
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Equation 2 
 
The pH of the buffer system can be altered by adjusting the concentration of the acid 
(H2CO3) and its conjugate base (HCO3
-) according to the Henderson–Hasselbalch equation 
(Equation 3). Purging carbon dioxide (g) to Hanks buffer, in excess, increases the 
concentration of aqueous (CO2) which promotes the formation of carbonic acid and thus 
results in a decrease in the pH of the buffer system. 
   
Equation 3  
 
In this experiment sufficient CO2 (g) is purged into the system to achieve the desired 
bicarbonate: carbonic acid ratio, which results in pH 6.8 bicarbonate buffer system 
(H2CO3 pKa, 6.38) while keeping the concentration of bicarbonate unchanged before and 
after modification. The concentration of bicarbonate in mHanks was determined using a 
titration method. A known amount of hydrochloric acid was added into mHanks buffer and 
the excess acid after neutralising bicarbonate is titrated with sodium hydroxide using 
Autotitrator MPT-2 (Malvern Instruments Ltd., Worcestershire, UK) and the endpoint was 
determined by a titration curve. The molar concentration of the reacted acid is equal to that 
of the bicarbonate in the sample; a correction factor is applied for the available phosphate 
species in the solution. The final ionic composition and buffer capacity of the mHanks buffer 
are compared with phosphate buffer and human jejunal fluid in Table 4.  
 
 
           CO2 (g) 
 
H2O + CO2(aq)    H2CO3   H
+  + HCO3
− 
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The pH in the dissolution media was measured at periodic intervals during the dissolution 
experiments and was maintained at 6.8 ± 0.05 by continuously sparging CO2 into the media. 
Six polyurethane flow tubes (Freshford Ltd., Manchester, UK), one for each dissolution 
vessel, were used to regulate the CO2 flow via a manifold assembly. 
 
Buffer capacity ( ) of the mHanks was measured by adding aliquots of 0.1M HCl to 100 ml of 
the buffer system.  Buffer capacity was then calculated using Equation 4.  
 
Equation 4 
where Δ AB is the small increment in mol/L of the amount of acid or base added to produce 
a pH change of Δ pH in the buffer. Buffer capacity was measured at a pH change of 0.5 units 
on addition of the acid. 
 
 
2.4.3 In vitro drug release 
The drug release profiles from the coated prednisolone tablets were carried out using a 
USP-II apparatus (Model PTWS, Pharmatest, Hainburg, Germany). The tests were conducted 
in triplicate, in 900 ml dissolution medium maintained at 37 + 0.5 °C. A paddle speed of 50 
rpm was employed. The tests were conducted under sink conditions. Tablets were placed for 
2 hours into 0.1 M HCl, and subsequently into pH 6.8 phosphate buffer (Composition: 50 
mM KH2PO4 and 23.5 mM NaOH; pH adjusted with 1M HCl / NaOH solutions) or pH 6.8 
mHanks buffer (Composition: 136.9 mM NaCl, 5.37 mM KCl, 0.812 mM MgSO4.7H2O, 1.26 
mM CaCl2, 0.337 mM Na2HPO4.2H2O, 0.441 mM KH2PO4, 4.17 mM NaHCO3, CO2 (g) quantity 
sufficient to reach pH 6.8) (Table 4). 
 
  P a g e  | 9 
The amount of prednisolone released from tablets coated with HPMCAS-LF, HPMCAS- MF, 
EUDRAGIT® L30D-55, L100-55 and L100 was determined using an in-line UV 
spectrophotometer (Cecil 2020, Cecil Instruments Ltd., Cambridge, UK) at the wavelength 
247 nm. Data were processed using Icalis software (Icalis Data Systems Ltd, Berkshire, UK). In 
the case of the tablets coated with CAP, HP-50, HP-55 and PVAP, drug release was 
determined using HPLC-UV due to the interference of UV absorbance of the polymers at the 
peak wavelength of prednisolone. 
 
The HPLC-UV system used was a Hewlett Packard 1050 Series HPLC system (Agilent 
Technologies, UK).  Dissolution samples were filtered through 0.22 µm filters (Millipore Ltd, 
Ireland) and ten microliters were then injected to a reverse phase C8 (5 m particle size) 
column (Waters, Massachusetts, USA). The chromatographic conditions were as follows: 
column temperature of 35 °C, a pressure of 1800 psi, mobile phase consisting of 
water: tetrahydrofuran: methanol (68.8:25:6.2 v/v), and a flow rate of 1.0 ml/min. 
Prednisolone was detected at the wavelength of 254 nm. 
 
The in vitro drug release data was analysed by two-way ANOVA followed by Tukey post-hoc 
analysis with 99.8% confidence interval using Univariate General Linear Model tool in PASW 
Statistics 18 (SPSS Inc., Illinois, USA). 
 
 
3. Results and discussion 
 
3.1 Acid resistance 
The acid uptake results for the various enteric formulations after exposure to 0.1 M HCl for 2 
h are shown in Table 5. All organic based enteric coating formulations showed low acid 
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uptake values at a coating level of 5 mg/cm2 (PVAP organic at 5% TWG), indicating good acid 
resistance. Notably, the aqueous dispersion of the methacrylic acid copolymer, EUDRAGIT® 
L30D-55, showed comparable acid-resistant properties to its organic version EUDRAGIT® 
L100-55, at the same coating level of 5 mg/cm2.  The aforementioned formulations remained 
intact and showed no physical changes after acid treatment.  
 
The aqueous cellulose based polymer HPMCAS-LF showed poor acid-resistance at 5 mg/cm2; 
acid uptake values were high and the tablets swelled in acid (Table 5). Therefore, higher 
coating levels (6, 7 and 8 mg/cm2) were investigated and a coating of 7 mg/cm2 was required 
for sufficient acid protection. This was also the case with HPMCAS-MF, which required a 
7 mg/cm2 coating level to achieve sufficient acid protection (Table 5). The aqueous coating 
formulation of PVAP (Sureteric®) also required a higher coating level (7% TWG) to achieve 
acid-resistance compared to its organic based counterpart (Opadry®) (5% TWG). The film 
forming mechanisms of the aqueous polymer dispersions are distinct from that of the 
organic solutions and require complete particle coalescence to obtain film coatings with 
desired properties [13, 38]; this results in the requirement of a higher coating level for the 
aqueous formulations to achieve adequate acid-resistance than organic formulations. 
 
The organic formulations with a coating level of 5 mg/cm2 and/or 5% TWG were further 
subjected to dissolution testing. The aqueous EUDRAGIT® L30D-55 formulation was also 
tested at a coating level of 5 mg/cm2. The remaining aqueous formulations were tested at 
7 mg/cm2 (HPMCAS-LF and HPMCAS-MF) and 7% TWG (PVAP aqueous / Sureteric®). 
 
3.2 Evolution of pH 6.8 bicarbonate buffer (mHanks) 
In the present study, pH 6.8 physiological bicarbonate buffer (mHanks buffer) was 
successfully developed by modification of Hanks buffer (pH 7.4). An attempt has been made 
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previously to develop pH 6.8 physiological bicarbonate buffers by sparging carbon dioxide to 
0.9% sodium chloride solution and the pH was achieved and maintained by titration using 
1 N sodium hydroxide [27]. Several issues related with this system were raised including the 
effect of thermal equilibrium on pH and buffer capacity, loss of carbon dioxide during 
transfer, cost, long set-up time and more profoundly bubble formation – changing the 
hydrodynamics of the system, resulting in high variability and poor reproducibility of the 
dissolution profiles [5]. A modified methodology was proposed later to overcome these 
issues by keeping sodium hydroxide at a constant concentration and maintaining the pH 
using carbon dioxide. However, maintaining the pH of this was problematic due to poor 
resistance of the buffer against pH change and consequently, much higher buffer capacity 
(30 mmoles/L/∆pH) was used for dissolution testing.  In the proposed mHanks physiological 
bicarbonate buffer in the present study, the desired pH was achieved and maintained by 
sparging carbon dioxide gas into the medium just 2 cm from the liquid surface at a very low 
flow rate compared to what has been used previously hence avoiding significant changes in 
hydrodynamics in the dissolution media. In addition, the mHanks closely resembles the ionic 
composition and buffer capacity of the luminal contents (Table 4), compared to the 
previously proposed media. 
 
3.3 Dissolution in buffer 
Drug release profiles for tablets coated with the organic and aqueous formulations in pH 6.8 
phosphate buffer post-exposure to 0.1 M HCl for 2 h are shown in Figures 1A and 2A. All 
enteric coating formulations, organic and aqueous, showed rapid and similar drug release 
profiles in pH 6.8 phosphate buffer. This buffer cannot tehrefore discriminate between the 
various polymers.  
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Drug release from prednisolone tablets coated with the organic and aqueous formulations in 
pH 6.8 mHanks buffer post-exposure to 0.1 M HCl for 2 h are shown in Figures 1B and 2B.  
Drug release was slower from all enteric coated tablets in pH 6.8 mHanks buffer, compared 
to that in pH 6.8 phosphate buffer. Moreover, distinctive dissolution profiles were observed 
for the various enteric coating formulations in this bicarbonate buffer. The dissolution 
profiles of the organic polymers in mHanks buffer (Figure 1B) are significantly different from 
each other, except HP-50 and HP-55. The dissolution rank order was EUDRAGIT® L100-55 > 
HP-55 ≈ HP-50 > PVAP > CAP > EUDRAGIT® L100.  
 
Similar to organic coatings, the enteric formulations based on aqueous polymer dispersions 
also showed slower drug release and a longer lag time in bicarbonate buffer as compared to 
compendial phosphate buffer.  Since aqueous coatings required a higher weight gain to 
achieve the sufficient acid resistance, as discussed earlier in section 3.1, therefore this higher 
weight gain resulted in a thicker coat as compared to their counterpart organic formulations. 
Consequently, the drug release in the buffer was slower from these aqueous coatings 
compared to organic coatings (Figure 1 and 2).  
 
In contrast to the aqueous formulations of PVAP and HPMCAS, the methacrylic acid 
copolymer EUDRAGIT® L30D-55 showed comparable acid resistant properties to its organic 
form (EUDRAGIT® L100-55) at 5 mg/cm2 coating level. Drug release from this aqueous 
coating system was similar to that from the organic coating system in pH 6.8 mHanks buffer 
(Figures 1B and 2B). Films formed from this aqueous polymeric dispersion has a minimum 
film formation temperature lower than room temperature (< 23 °C), and the particles in the 
latex EUDRAGIT® L30D-55 dispersion have relatively small size (the mean particle size of 
0.2 μm) [24]. These properties of the dispersion provide easy particle coalescence during 
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film formation, and ensured comparable properties of the aqueous film coating as the 
organic coating.  
 
 
3.4 Distinct behaviour of enteric formulations in physiological bicarbonate media: 
mechanistic explanation 
The mechanism of carboxylic acid polymer dissolution in aqueous solutions is different  than 
that of non-ionic polymers [28] because it involves an additional ionization step that 
stabilizes the polymer chains. The process of dissolution consists of five steps; (i) diffusion of 
water and hydroxyl ions into the polymer matrix to form a gel layer, (ii) ionization of polymer 
chains in the gel layer, (iii) disentanglement of polymer chains out of the gel layer to the 
polymer-solution interface, (iv) further ionization of polymer chains at the polymer 
interface, (v)  diffusion of disentangled polymer chains away from the interface towards the 
bulk solution [30]. The rank order in the dissolution of organic polymers observed in mHanks 
buffer, given the same coating levels were applied, can be explained by the determinant 
factors for enteric coating dissolution: polymer pKa and chemical structure [31]. Polymers 
with higher pKa values reflected by higher dissolution pH thresholds, such as 
EUDRAGIT® L100, showed slower drug release. Apart from pKa, structure of the polymer 
back bone is also an important factor controlling the dissolution of polyacid polymers. For 
instance, CAP has a water insoluble back bone and dissolves slower than HPMCP (HP-50/HP-
55) and PVAP which have water soluble back bones [10]. 
 
Similar to the intestinal fluids, the mHanks buffer is buffered by bicarbonate and also closely 
resembles the luminal fluids in terms of ionic composition and strength and buffer capacity 
in contrast to the compendial phosphate buffer. It is notable that drug release in pH 6.8 
mHanks buffer was considerably slower than in the compendial phosphate buffer; it not only 
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discriminated between the different enteric polymer coatings, but is indeed better reflective 
to the delayed disintegration of enteric coated products in the human intestine in vivo [4, 8, 
12, 20, 39]. This confirms that most of the enteric coating systems are not interchangeable in 
terms of drug release as would be suggested by the release data in phosphate buffer, and 
provides a rank order for these systems in terms of dissolution. To understand this distinct 
behaviour of enteric polymers in mHanks, it is important to understand the interaction of 
the functional groups at the polymer chain with various ions and buffer species present in 
the dissolution media. 
 
There have been several reports in the literature, where extremely low rate of dissolution of 
enteric polymers were reported in normal saline or very weak buffer solutions at pH well 
above the dissolution thresholds, whereas fast dissolution was observed at same pH at 
relatively higher strength buffers [15, 31, 36, 37] suggesting that pH is not the only factor 
controlling the drug release from enteric polymers and other factors also affect the 
dissociation of the polymer chains.  The composition of the dissolution medium, especially 
the buffer salt, profoundly influences the dissolution rate of enteric polymers. The influence 
of salts in dissolution of enteric polymers can be explained by general base catalysis. The 
acid polymers (R-COOH) dissociate through proton transfer to the Brönsted base (H2O), 
resulting in the formation of the conjugate base of the polymer and hydronium ions 
(Equation 5A). In the presence of a basic salt (e.g. HCO3
- or HPO4
-), the rate of proton 
transfer is increased by the higher affinity of the water in accepting proton and consequently 
the dissolution rate is increased (Equation 5B and 5C). By obeying the Brönsted catalysis law, 
the dissolution rate was found directly proportional to the pKa and the concentration of the 
salts present in the solution [36].  
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Equation 5. Ionization of carboxylic group in polymer in aqueous media containing [A] only water,  
[B] phosphate and [C] bicarbonate species 
 
It was also explained that apart from pKa, buffer capacity of the salts also affects acidic 
polymer dissolution [34]. Hydrogen ions are generated at the polymer-solution interface 
during polymer dissociation [30] and contribute to a pH drop near the surface of the 
dissolving carboxylic polymer [21]. Removal of these hydrogen ions at the interface 
increases the polymer dissolution rate and can be facilitated by reacting with proton 
acceptors (buffer species), depending on their buffer capacities which directly link to the pKa 
of the buffer salt. Phosphate buffer has an effective pKa of 7.19 and a resultant higher buffer 
capacity (23 mmol/L/∆pH) thus provides greater driving force for the acidic polymer 
dissolution than that of bicarbonate with a pKa of 6.31 and a much lower buffer capacity 
(3.1 mmol/L/∆pH). Sheng et al has also suggested that pKa differences in these two buffer 
species results in different buffer capacity at the solid-liquid interface; where phosphate 
buffer had about 23 % higher buffer capacity relative to the bicarbonate, at the same pH and 
buffer concentration [35]. Ionic strength of the dissolution media also have a profound 
effect on the reaction rate between the polymer film and the basic buffer species; a drastic 
change in the dissolution rate has been reported from enteric coated formulations with 
change in ionic strengths of the media [15, 23, 29]. 
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Hence, the pH 6.8 physiological mHanks bicarbonate buffer is more appropriate as a 
dissolution medium to assess the in vitro dissolution of enteric polymer coated systems. 
Further investigations are required to simulate other conditions of the luminal fluids in vitro 
by means of media volume, viscosity and hydrodynamics and a more discriminative effect on 
drug release can be expected. 
 
 
4. Conclusions 
Drug release from the different enteric coated formulations investigated was rapid and 
comparable in the commonly used compendial pH 6.8 phosphate buffer, failing to reflect the 
reported in vivo variation and slow release of enteric coated products. A pH 6.8 physiological 
bicarbonate (mHanks) buffer was developed as a dissolution medium to better simulate 
small intestinal luminal fluid. This buffer was able to discriminate the different enteric 
polymer coated systems, providing a rank dissolution order, and is likely to improve the 
in vitro-in vivo correlations of these modified release systems. This new knowledge can also 
be useful in the rational design of enteric coated products designed to target different sites 
in the small bowel, such as the proximal small intestine or the mid small intestine.  
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Table 1. Enteric polymers used in the study    
 
Polymer Brand name Abbreviation Grade Soluble at 
or above 
pH 
Manufacturer/ 
Supplier 
Methacrylic acid 
copolymer 
 
EUDRAGIT® - L 100-55  5.5 Evonik Röhm 
GmbH, 
Darmstadt, 
Germany L 30D-55  5.5 
L100 6.0  
Hypromellose 
acetate 
succinate 
Aqoat® HPMCAS LF 5.0 Shin-Etsu 
Chemical Co., 
Ltd., Japan 
  MF 6.0 
Hypromellose 
phthalate 
- HPMCP  HP-50 
 
HP-55 
5.0 
 
5.5 
 
Shin-Etsu 
Chemical Co., 
Ltd., Japan 
Cellulose 
acetate 
phthalate 
- CAP - 6.0 Eastman 
Chemical 
Company, USA 
Polyvinyl 
acetate 
phthalate 
*Opadry®  
Enteric 
PVAP Organic 5.0 Colorcon Ltd., 
USA. 
 **Sureteric®  Aqueous 
 
5.0  
 
* Fully formulated coating system containing: PVAP, titanium dioxide, triethyl citrate and stearic acid 
** Fully formulated coating system containing: PVAP, talc, polyethylene glycol 3350, sodium 
bicarbonate, triethyl citrate, purified stearic acid, sodium alginate and colloidal anhydrous silica 
 
Table(s)
Table 2. Composition of the coating formulations  
 
[A] Aqueous formulations 
 EUDRAGIT®  
L30 D-55 
PVAP (aqueous) HPMCAS-LF HPMCAS-MF 
Polymer weight 20g 20g 20g 20g 
Talc 10g (50%*) - 6g (30%*) 6g (30%*) 
Triethyl citrate 2g (10%)* - 4g (20%*) 4g (20%*) 
Sodium lauryl sulphate - - 0.6g (3%*) 0.6g (3%*) 
Water 128g 113.3g 352g 352g 
Solid content of the 
spray suspension 
20% 15% 8% 8%   
*Based on polymer weight 
 
[B] Organic formulations  
 EUDRAGIT® 
L100-55 
EUDRAGIT® 
L100 
PVAP 
(organic) 
CAP HP-50 HP-55 
Polymer weight 20g 20g 20g 20g 20g 20g 
Talc 10g  
(50%*) 
10g  
(50%*) 
- 10g  
(50%*) 
10g  
(50%*) 
10g  
(50%*) 
Triethyl citrate 2g  
(10%*) 
2g  
(10%*) 
- - 2g  
(10%*) 
2g  
(10%*) 
Triacetin - - - 5g  
(25%*) 
- - 
Isopropanol 279.4g  
(97%**) 
279.4g  
(97%**) 
144g  
(80%**) 
- - - 
Ethanol - - - - 230.4g 
(80%**) 
230.4g 
(80%**) 
Acetone - - - 249g 
(97%**) 
- - 
Water 8.6g  
(3%**) 
8.6g  
(3%**) 
36g  
(20%**) 
7.7g 
(3%**) 
57.6g 
(20%**) 
57.6g 
(20%**) 
Solid content of 
the spray 
suspension 
10% 10% 10% 12% 10% 10% 
*Based on polymer weight. ** Based on solvent weight. 
 
  
Table 3. Coating parameters for the different polymer systems  
Formulation Inlet 
temp 
(°C) 
Outlet 
temp 
 (°C) 
Fan 
capacity 
Atomizing 
pressure 
(bar) 
Flow rate 
(mL/min) 
Coating level 
(mg/cm2) 
EUDRAGIT® L30D-55 46 34 17 0.2 4 5 
EUDRAGIT® L100-55 40 32 17 0.2 3 5 
EUDRAGIT® L100 40 32 17 0.2 3 5 
AS-LF 46 43 17 0.2 7 5,6,7,8 
AS-MF 56 60 17 0.2 7 5 
PVAP(Sureteric®) 58 43 17 0.2 7 5, 
6,7,8% TWG 
PVAP (Opadry®) 52 40 9 0.2 7 5% TWG 
CAP 40 34 17 0.2 5 5 
HP-50 46 38 17 0.2 4 5 
HP-55 60 43 17 0.2 5 5 
 
  
Table 4. Comparison of the ionic composition (mM) and buffer capacity of small intestinal 
fluids [2, 25, 32] and phosphate and mHanks media. 
Composition  
 
Human jejunal 
fluid 
 
Phosphate 
buffer (0.05M) 
mHanks buffer 
Bicarbonate 7.1 Not present 4.17 
Phosphate 0.8 50 0.8 
Potassium 5.1 50 5.8 
Sodium 142 29 142 
Chloride 131 Not present 143 
Calcium 0.5 Not present 1.3 
Magnesium  Not present 0.8 
pH 6.8 6.8 6.8 
Buffer capacity 
(mmol/L/∆pH) 3.2† 23 3.1 
† measured from luminal aspirates [16]. 
Table 5. Acid uptake of enteric coated prednisolone tablets  
[A] Organic formulations 
 
CAP  
EUDRAGIT® L 
100 
EUDRAGIT®  
L100-55 
HP-50 HP-55 PVAP* (Opadry®) 
Coating Level 
(mg/cm2) 
5† 5† 5† 5† 5† 5%† 
Acid uptake 
(%) 
2.6 4.2 2.7 2.8 2.1 1.2 
 
 
[B] Aqueous formulations 
 
EUDRAGIT®  
L30D-55 
HPMCAS-LF HPMCAS-MF PVAP* (Sureteric®) 
Coating level 
(mg/cm2) 
5† 5 6 7† 8 5 6 7† 5% 6% 7%† 8% 
Acid uptake 
(%) 
3.1 19.4 7.8 7.5 6 9.9 
 
7.8 
 
5.5 
 
30.3 14 8.3 7.2 
 
* coating level based on tablet weight gain (%) 
† coating levels selected for dissolution testing 
 
  
 
Figure 1. Drug release for organic solution coated (5mg/cm2 unless otherwise indicated) 
prednisolone tablets in 0.1M HCl for 2h (data not shown) followed by pH 6.8 [A] phosphate 
buffer and [B] bicarbonate buffer 
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Figure 2.  Drug release for aqueous dispersion coated prednisolone tablets in 0.1M HCl  
for 2h (data not shown) followed by pH 6.8 [A] phosphate buffer and [B] bicarbonate buffer 
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